Ai Biotechnology Llc Purchases 2,000,000 Shares of Zura Bio (NASDAQ:ZURA) Stock

Zura Bio Limited (NASDAQ:ZURA) major shareholder Ai Biotechnology Llc bought 2,000,000 shares of the stock in a transaction dated Thursday, February 26th. The stock was bought at an average price of $6.25 per share, with a total value of $12,500,000.00. Following the purchase, the insider owned 6,552,725 shares of the company’s stock, valued at approximately $40,954,531.25. This represents a 43.93% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Zura Bio Stock Performance

Shares of ZURA stock traded up $0.14 on Monday, hitting $6.76. The stock had a trading volume of 421,166 shares, compared to its average volume of 727,424. The stock’s 50 day moving average is $5.68 and its 200-day moving average is $4.08. The firm has a market capitalization of $439.56 million, a price-to-earnings ratio of -10.40 and a beta of 0.21. Zura Bio Limited has a 52-week low of $0.97 and a 52-week high of $7.19.

Analyst Ratings Changes

A number of equities analysts have commented on ZURA shares. Leerink Partners raised shares of Zura Bio to a “strong-buy” rating in a report on Sunday, November 23rd. Wall Street Zen cut shares of Zura Bio from a “hold” rating to a “sell” rating in a report on Sunday, November 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Zura Bio in a research report on Friday, January 9th. Wedbush started coverage on Zura Bio in a research note on Monday, February 9th. They set an “outperform” rating and a $15.00 price objective for the company. Finally, Chardan Capital restated a “buy” rating and set a $10.00 price target on shares of Zura Bio in a report on Friday, November 14th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.60.

Institutional Investors Weigh In On Zura Bio

Several hedge funds have recently bought and sold shares of ZURA. JPMorgan Chase & Co. grew its stake in Zura Bio by 78.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock valued at $4,893,000 after acquiring an additional 2,052,732 shares in the last quarter. Siren L.L.C. purchased a new stake in shares of Zura Bio in the fourth quarter worth approximately $6,812,000. Boothbay Fund Management LLC acquired a new stake in shares of Zura Bio during the third quarter worth approximately $3,568,000. VR Adviser LLC boosted its holdings in shares of Zura Bio by 15.4% during the fourth quarter. VR Adviser LLC now owns 5,345,115 shares of the company’s stock worth $28,008,000 after purchasing an additional 713,899 shares during the period. Finally, Braidwell LP grew its position in Zura Bio by 28.6% during the fourth quarter. Braidwell LP now owns 3,180,389 shares of the company’s stock valued at $16,665,000 after purchasing an additional 707,583 shares in the last quarter. 61.14% of the stock is owned by hedge funds and other institutional investors.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.